A new market research report on the Global Intravenous Immunoglobulin (IVIG) market has introduced by KD Market Insights. The report is dedicated to in-depth industry analysis of the global Intravenous Immunoglobulin (IVIG) market. The Global Intravenous Immunoglobulin (IVIG) analysis is broken down on different segmentation levels including Market By Application, By Type.
The global intravenous immunoglobulin (IGIV) market was valued at $8,995 million in 2017and is projected to reach $15,964 million by 2025, registering a CAGR of 7.5% from 2018 to 2025. Immunoglobulins (IGs), also referred to as antibodies, are glycoproteins produced by the blood plasma in response to foreign bodies or antigens. They are highly complex entities and are specific in their action. These immunoglobulins are obtained from blood through the process of fractionation and are purified for use in therapeutic and nontherapeutic areas.
Get Report Sample Copy @ https://www.kdmarketinsights.com/sample/3385
Increase in prevalence of immunodeficiency and autoimmune diseases such as chronic inflammatory demyelinating polyneuropathy, hypogammaglobulinemia, & others and rise in adoption of immunoglobulin therapies for the treatment of various autoimmune disorders majorly drive the growth of the IVIG market. Furthermore, increase in approval of IVIG drugs from the Food and Drug Administration (FDA), European Medicine Agency (EMA), and other government agencies is expected to accelerate the growth of the IVIG industry. However, stringent government regulations toward the vigorous use of immunoglobulins, inflated cost of therapy, and high risk of side effects associated with the use of immunoglobulin intravenously are anticipated to hamper the market growth. On the contrary, significant investment in healthcare sector is expected to provide lucrative opportunities for the market growth in the near future.
The global intravenous immunoglobulin (IVIG) market is characterized based on application, type, and region. By application, the market is segmented into hypogammaglobulinemia, CIDP, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, Guillain Barre syndrome, and others. Depending on type, it is classified into IgG, IgA, IgM, IgE, and IgD. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits for Intravenous Immunoglobulin Market:
- The report provides an in-depth analysis of the intravenous immunoglobulin market along with the current trends and future estimations to elucidate the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the market growth is provided in this study.
- The report provides a detailed quantitative analysis of the industry from 2018 to 2025 to assist stakeholders to capitalize on the prevailing market opportunities.
- An extensive analysis of the key segments of the industry helps to understand the trends in the intravenous immunoglobulin market globally.
Key players and their strategies are provided to understand the competitive outlook of the industry.
Intravenous Immunoglobulin Key Market Segments:
By Application
- Hypogammaglobulinemia
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Primary Immunodeficiency Disease
- Myasthenia Gravis
- Multifocal Motor Neuropathy
- Idiopathic Thrombocytopenic Purpura (ITP)
- Inflammatory Myopathies
- Specific Antibody Deficiency
- Guillain Barre Syndrome
- Others
By Type
- IgG
- IgA
- IgM
- IgE
- IgD
By Region
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- France
- Germany
- Italy
- France
- Austria
- Russia
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
LAMEA
- Brazil
- Argentina
- Turkey
- Saudi Arabia
- Rest of LAMEA
Key Players Profiled
- Baxter international Inc.
- CSL Ltd.
- Grifols, S.A.
- Octapharma AG
- Kedrion Biopharma Inc.
- LFB Group
- Biotest AG
- China Biologics Products, Inc.
- Takeda Pharmaceuticals
- Bayer AG
Access Complete Research Report with TOC @ https://www.kdmarketinsights.com/product/intravenous-immunoglobulin-market-amr
Table of Content
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Overview of Immunoglobulin
3.2.1. Patented products
3.2.2. Epidemiology and economic burden of chronic conditions
3.3. Key findings
3.3.1. Top Investment Pockets
3.4. Porters five forces analysis
3.5. Value chain analysis
3.5.1. Primary activities
3.5.2. Support activities
3.6. Market share analysis, 2017
3.7. Product scenario in intravenous immunoglobulin market
3.8. Government regulations and reimbursements
3.8.1. U.S.
3.8.2. Europe
3.8.3. France
3.8.4. Germany
3.8.5. Italy
3.8.6. China
3.8.7. Japan
3.8.8. India
3.9. Indications for immunoglobulin
3.9.1. U.S. FDA indications
3.9.2. EMA
3.10. Component analysis of immunoglobulin G (IgG)
3.10.1. IgG1
3.10.2. IgG2
3.10.3. IgG3
3.10.4. IgG4
3.11. Market dynamics
3.11.1. Drivers
3.11.1.1. Rise in prevalence of immunodeficiency diseases
3.11.1.2. Increase in adoption of immunoglobulin treatment
3.11.1.3. Growth in incidence of bleeding disorders
3.11.2. Restraints
3.11.2.1. Stringent government regulations
3.11.2.2. High cost of therapy
3.11.3. Opportunities
3.11.3.1. Opportunities in emerging economies
3.11.3.2. Development of cost-effective therapeutics through large-scale production
CHAPTER 4: IMMUNOGLOBULIN MARKET, BY APPLICATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Hypogammaglobulinemia
4.2.1. Market size and forecast
4.3. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
4.3.1. Market size and forecast
4.4. Primary immunodeficiency diseases
4.4.1. Market size and forecast
4.5. Myasthenia Gravis
4.5.1. Market size and forecast
4.6. Multifocal motor neuropathy
4.6.1. Market size and forecast
4.7. Idiopathic thrombocytopenic purpura (ITP)
4.7.1. Market size and forecast
4.8. Inflammatory myopathies
4.8.1. Market size and forecast
4.9. Specific antibody deficiency
4.9.1. Market size and forecast
4.10. Guillain-Barre syndrome
4.10.1. Market size and forecast
4.11. Others
4.11.1. Market size and forecast
CHAPTER 5: IMMUNOGLOBULIN MARKET, BY PRODUCT
5.1. Overview
5.1.1. IGG
5.1.1.1. Key market trends
5.1.2. Clinical interpretations
5.1.3. IGA
5.1.3.1. Key Market Trends
5.1.4. Clinical interpretation
5.1.5. IGM
5.1.5.1. Key Market Trends
5.1.6. Clinical interpretation
5.1.7. IGE
5.1.7.1. Key Market Trend
5.1.8. Clinical interpretation
5.1.9. IGD
5.1.9.1. Key Market Trends
5.1.10. Clinical interpretation
CHAPTER 6: INTRVAENOUS IMMUNOGLOBULIN MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key trends and opportunities
6.2.2. North America market size & forecast, by application
6.2.3. North America market size & forecast, by country
6.2.3.1. U.S. market size & forecast
6.2.3.2. Canada market size & forecast
6.2.3.3. Mexico market size & forecast
6.3. Europe
6.3.1. Key trends and opportunities
6.3.2. Europe market size & forecast, by application
6.3.3. Europe market size & forecast for immunoglobulin market, by country
6.3.3.1. Germany market size & forecast
6.3.3.2. France market size & forecast
6.3.3.3. UK market size & forecast
6.3.3.4. Italy market size & forecast
6.3.3.5. Austria market size & forecast
6.3.3.6. Russia market size & forecast
6.3.3.7. Rest of Europe market size & forecast
6.4. Asia-Pacific
6.4.1. Key trends and opportunities
6.4.2. Asia-Pacific market size & forecast, by application
6.4.3. Asia-Pacific market size & forecast, by country
6.4.3.1. Australia market size & forecast
6.4.3.2. China market size & forecast
6.4.3.3. India market size & forecast
6.4.3.4. Japan market size & forecast
6.4.3.5. Rest of Asia-Pacific market size & forecast
6.5. LAMEA
6.5.1. Key trends and opportunities
6.5.2. LAMEA market size & forecast, by application
6.5.3. LAMEA market size & forecast, by country
6.5.3.1. Brazil market size & forecast
6.5.3.2. Saudi Arabia market size & forecast
6.5.3.3. Argentina market size & forecast
6.5.3.4. Turkey market size & forecast
6.5.3.5. Rest of LAMEA market size & forecast
Continue @...
Check for Discount @ https://www.kdmarketinsights.com/discount/3385
About Us:
KD Market Insights offers a comprehensive database of syndicated research studies, customized reports, and consulting services. These reports are created to help in making smart, instant and crucial decisions based on extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Our dedicated in-house team ensures the reports satisfy the requirement of the client. We aim at providing value service to our clients. Our reports are backed by extensive industry coverage and is made sure to give importance to the specific needs of our clients. The main idea is to enable our clients to make an informed decision, by keeping them and ourselves up to date with the latest trends in the market.
Contact Us:
KD Market Insights
150 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Email: sales@kdmarketinsights.com
Website: http://www.kdmarketinsights.com
Read More:
https://pr-wire.blogspot.com/
https://dailyprpost.blogspot.com/
The global intravenous immunoglobulin (IGIV) market was valued at $8,995 million in 2017and is projected to reach $15,964 million by 2025, registering a CAGR of 7.5% from 2018 to 2025. Immunoglobulins (IGs), also referred to as antibodies, are glycoproteins produced by the blood plasma in response to foreign bodies or antigens. They are highly complex entities and are specific in their action. These immunoglobulins are obtained from blood through the process of fractionation and are purified for use in therapeutic and nontherapeutic areas.
Get Report Sample Copy @ https://www.kdmarketinsights.com/sample/3385
Increase in prevalence of immunodeficiency and autoimmune diseases such as chronic inflammatory demyelinating polyneuropathy, hypogammaglobulinemia, & others and rise in adoption of immunoglobulin therapies for the treatment of various autoimmune disorders majorly drive the growth of the IVIG market. Furthermore, increase in approval of IVIG drugs from the Food and Drug Administration (FDA), European Medicine Agency (EMA), and other government agencies is expected to accelerate the growth of the IVIG industry. However, stringent government regulations toward the vigorous use of immunoglobulins, inflated cost of therapy, and high risk of side effects associated with the use of immunoglobulin intravenously are anticipated to hamper the market growth. On the contrary, significant investment in healthcare sector is expected to provide lucrative opportunities for the market growth in the near future.
The global intravenous immunoglobulin (IVIG) market is characterized based on application, type, and region. By application, the market is segmented into hypogammaglobulinemia, CIDP, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, Guillain Barre syndrome, and others. Depending on type, it is classified into IgG, IgA, IgM, IgE, and IgD. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits for Intravenous Immunoglobulin Market:
- The report provides an in-depth analysis of the intravenous immunoglobulin market along with the current trends and future estimations to elucidate the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the market growth is provided in this study.
- The report provides a detailed quantitative analysis of the industry from 2018 to 2025 to assist stakeholders to capitalize on the prevailing market opportunities.
- An extensive analysis of the key segments of the industry helps to understand the trends in the intravenous immunoglobulin market globally.
Key players and their strategies are provided to understand the competitive outlook of the industry.
Intravenous Immunoglobulin Key Market Segments:
By Application
- Hypogammaglobulinemia
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Primary Immunodeficiency Disease
- Myasthenia Gravis
- Multifocal Motor Neuropathy
- Idiopathic Thrombocytopenic Purpura (ITP)
- Inflammatory Myopathies
- Specific Antibody Deficiency
- Guillain Barre Syndrome
- Others
By Type
- IgG
- IgA
- IgM
- IgE
- IgD
By Region
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- France
- Germany
- Italy
- France
- Austria
- Russia
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
LAMEA
- Brazil
- Argentina
- Turkey
- Saudi Arabia
- Rest of LAMEA
Key Players Profiled
- Baxter international Inc.
- CSL Ltd.
- Grifols, S.A.
- Octapharma AG
- Kedrion Biopharma Inc.
- LFB Group
- Biotest AG
- China Biologics Products, Inc.
- Takeda Pharmaceuticals
- Bayer AG
Access Complete Research Report with TOC @ https://www.kdmarketinsights.com/product/intravenous-immunoglobulin-market-amr
Table of Content
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Overview of Immunoglobulin
3.2.1. Patented products
3.2.2. Epidemiology and economic burden of chronic conditions
3.3. Key findings
3.3.1. Top Investment Pockets
3.4. Porters five forces analysis
3.5. Value chain analysis
3.5.1. Primary activities
3.5.2. Support activities
3.6. Market share analysis, 2017
3.7. Product scenario in intravenous immunoglobulin market
3.8. Government regulations and reimbursements
3.8.1. U.S.
3.8.2. Europe
3.8.3. France
3.8.4. Germany
3.8.5. Italy
3.8.6. China
3.8.7. Japan
3.8.8. India
3.9. Indications for immunoglobulin
3.9.1. U.S. FDA indications
3.9.2. EMA
3.10. Component analysis of immunoglobulin G (IgG)
3.10.1. IgG1
3.10.2. IgG2
3.10.3. IgG3
3.10.4. IgG4
3.11. Market dynamics
3.11.1. Drivers
3.11.1.1. Rise in prevalence of immunodeficiency diseases
3.11.1.2. Increase in adoption of immunoglobulin treatment
3.11.1.3. Growth in incidence of bleeding disorders
3.11.2. Restraints
3.11.2.1. Stringent government regulations
3.11.2.2. High cost of therapy
3.11.3. Opportunities
3.11.3.1. Opportunities in emerging economies
3.11.3.2. Development of cost-effective therapeutics through large-scale production
CHAPTER 4: IMMUNOGLOBULIN MARKET, BY APPLICATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Hypogammaglobulinemia
4.2.1. Market size and forecast
4.3. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
4.3.1. Market size and forecast
4.4. Primary immunodeficiency diseases
4.4.1. Market size and forecast
4.5. Myasthenia Gravis
4.5.1. Market size and forecast
4.6. Multifocal motor neuropathy
4.6.1. Market size and forecast
4.7. Idiopathic thrombocytopenic purpura (ITP)
4.7.1. Market size and forecast
4.8. Inflammatory myopathies
4.8.1. Market size and forecast
4.9. Specific antibody deficiency
4.9.1. Market size and forecast
4.10. Guillain-Barre syndrome
4.10.1. Market size and forecast
4.11. Others
4.11.1. Market size and forecast
CHAPTER 5: IMMUNOGLOBULIN MARKET, BY PRODUCT
5.1. Overview
5.1.1. IGG
5.1.1.1. Key market trends
5.1.2. Clinical interpretations
5.1.3. IGA
5.1.3.1. Key Market Trends
5.1.4. Clinical interpretation
5.1.5. IGM
5.1.5.1. Key Market Trends
5.1.6. Clinical interpretation
5.1.7. IGE
5.1.7.1. Key Market Trend
5.1.8. Clinical interpretation
5.1.9. IGD
5.1.9.1. Key Market Trends
5.1.10. Clinical interpretation
CHAPTER 6: INTRVAENOUS IMMUNOGLOBULIN MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key trends and opportunities
6.2.2. North America market size & forecast, by application
6.2.3. North America market size & forecast, by country
6.2.3.1. U.S. market size & forecast
6.2.3.2. Canada market size & forecast
6.2.3.3. Mexico market size & forecast
6.3. Europe
6.3.1. Key trends and opportunities
6.3.2. Europe market size & forecast, by application
6.3.3. Europe market size & forecast for immunoglobulin market, by country
6.3.3.1. Germany market size & forecast
6.3.3.2. France market size & forecast
6.3.3.3. UK market size & forecast
6.3.3.4. Italy market size & forecast
6.3.3.5. Austria market size & forecast
6.3.3.6. Russia market size & forecast
6.3.3.7. Rest of Europe market size & forecast
6.4. Asia-Pacific
6.4.1. Key trends and opportunities
6.4.2. Asia-Pacific market size & forecast, by application
6.4.3. Asia-Pacific market size & forecast, by country
6.4.3.1. Australia market size & forecast
6.4.3.2. China market size & forecast
6.4.3.3. India market size & forecast
6.4.3.4. Japan market size & forecast
6.4.3.5. Rest of Asia-Pacific market size & forecast
6.5. LAMEA
6.5.1. Key trends and opportunities
6.5.2. LAMEA market size & forecast, by application
6.5.3. LAMEA market size & forecast, by country
6.5.3.1. Brazil market size & forecast
6.5.3.2. Saudi Arabia market size & forecast
6.5.3.3. Argentina market size & forecast
6.5.3.4. Turkey market size & forecast
6.5.3.5. Rest of LAMEA market size & forecast
Continue @...
Check for Discount @ https://www.kdmarketinsights.com/discount/3385
About Us:
KD Market Insights offers a comprehensive database of syndicated research studies, customized reports, and consulting services. These reports are created to help in making smart, instant and crucial decisions based on extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Our dedicated in-house team ensures the reports satisfy the requirement of the client. We aim at providing value service to our clients. Our reports are backed by extensive industry coverage and is made sure to give importance to the specific needs of our clients. The main idea is to enable our clients to make an informed decision, by keeping them and ourselves up to date with the latest trends in the market.
Contact Us:
KD Market Insights
150 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Email: sales@kdmarketinsights.com
Website: http://www.kdmarketinsights.com
Read More:
https://pr-wire.blogspot.com/
https://dailyprpost.blogspot.com/
No comments:
Post a Comment